It was a pleasure to meet with Lawrence Steinman (Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA, USA), to discuss the results from the Phase 3 ULTIMATE I and II trials, investigating ublituximab versus teriflunomide in relapsing multiple sclerosis.
The abstract entitled: ‘Ublituximab versus teriflunomide in relapsing multiple sclerosis (RMS): Results of the Phase 3 ULTIMATE I and II trials’ was presented at the 7th Congress of the European Academy of Neurology – Virtual 2021, 18-22 June 2021.
Questions:
- What are the potential advantages of ublituximab compared with other anti-CD20 antibodies used in the management of relapsing multiple sclerosis (MS)? (0:25)
- How well were the primary and secondary efficacy and safety endpoints met in the ULTIMATE-I and ULTIMATE-II studies? (2:45)
- What will be the next step in the clinical development of ublituximab? (4:46)
- Where do you envisage ublituximab sitting in the treatment paradigm for MS? (5:15)
Disclosures: Lawrence Steinman is a consultant for TGTx.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch
Filmed as a highlight of the EAN Congress, Virtual 2021.
